Clinical transformation of immunotherapy with extracellular vesicles on the tuyere for tackling major diseases

China is speeding up the examination and approval of market access for major disease treatment technologies with clear efficacy and safety. A few days ago, Hubei Medical Insurance Bureau and Health Commission approved a batch of new medical service projects. Among them, the drug loaded vesicle treatment technology independently developed by shengqi’an biology was officially included, and the price approval document was obtained. This means that the technology can be used in the clinical application of malignant pleural effusion and cholangiocarcinoma and other indications, and can be commercially sold to benefit more patients. “< / P > < p >” drug loaded vesicle therapy is a new targeted tumor treatment mode. ” According to Meng Fanfan, President of shengqi’an biology, vesicle is a vesicular structure that peels off the surface of cell membrane during cell activation or apoptosis, and is a kind of biological information carrier. The technology of drug-loaded vesicle therapy for cancer is simply to “put explosives” – a small amount of chemotherapy drugs in the tumor cells’ vesicles, and then transport the drug loaded vesicles back to the patient’s body to accurately target and “kill” the tumor cells. This technology is also known as the “wolf in sheep’s clothing”. At present, in the field of tumor immunotherapy, drug loaded vesicle therapy is one of the hot research fields. Meng Fanfan said that the treatment of diseases by extracellular vesicles represented by drug loaded vesicles has been widely studied worldwide. < p > < p > among them, shengqi’an Biological Technology Co., Ltd. is the first innovative enterprise in China to research and develop drug loaded vesicle treatment technology, and takes the lead in realizing clinical transformation. Up to now, shengqi’an biological has carried out clinical cooperation with more than 60 mainstream tertiary hospitals in China. At present, the indications on the market include malignant pleural effusion and cholangiocarcinoma, and the indications to be put on the market include lung cancer, gastric cancer, liver cancer, esophageal cancer, malignant ascites, etc., so as to create a stable and sustainable product development pipeline. < / P > < p > as a global leading, innovative and cutting-edge cancer treatment technology, after clarifying the safety and effectiveness of the technology, combining with the characteristics of the project itself, actively comply with the government policy guidance, enter the market with new medical technology mode, complete the “last mile” of clinical transformation, and carry out clinical application as soon as possible, which is the innovation of “government, industry, University, research and application” in China Achievements and products under the system. < / P > < p > in 2019, the national development and Reform Commission will jointly issue the report. Ten major projects were launched to promote the high-quality development of health industry. Among them, we should accelerate the research and transformation of key technologies such as tumor biological immunotherapy, and break through the bottleneck of neck sticking technology in the field of cancer treatment in China by encouraging innovation and implementation. Specifically speaking, the new medical technology mode is to sign medical technical service contract between enterprises and hospitals, and the hospital will carry out clinical application, which is also the direction and trend of deepening the reform of medical and health system in China. Up to now, the technology has been approved to be used in Anhui, Hubei, Hunan, Hebei, Tianjin, Shandong and Shenzhen. It has become one of the first new medical technology companies to complete the clinical transformation of major diseases under the policy encouragement, and leads the world in the blue sea track based on extracellular vesicles. < / P > < p > “the global heat for extracellular vesicles is unprecedented, and the research on it is just on the rise. Most of the research and transformation enterprises in this field are in the stage of basic research or clinical phase 1, and there are relatively few competitors on this track.” Meng Fanfan said that drug loaded vesicles, as a new type of anti-tumor technology with independent source innovation in China, have completed clinical transformation and come into the market, leading the world in the transformation speed in the field of extracellular vesicle therapy for cancer. According to a report released by Hengzhou Bozhi information consulting, in recent years, the global pleural effusion treatment market has developed rapidly. Among them, the global revenue in 2018 was close to 4.23 billion US dollars, and that in 2019 was 4.482 billion US dollars. The average market growth rate was 5.91%, and the compound annual growth rate was expected to be 6.60% from 2020 to 2026. At present, there is no universal gold standard for the treatment of malignant pleural effusion in China. Most of the existing treatment methods are symptomatic and palliative. < / P > < p > “with the resource integration and joint efforts of various parties in the innovation system of government, industry, University, research and application, China has the strength and ability to realize independent innovation on the biological track.” Meng Fanfan said that as clinical experts have more extensive knowledge and recognition of technology, talents are also accelerating to gather in enterprises, forming a benign interaction between industry, University and Research Institute. < / P > < p > as the technology is used in various provinces and cities, it will benefit more patients. It is expected that in the future cancer treatment market, it will bring huge economic benefits to China’s biomedical industry, and bring great innovation to the treatment of various types of malignant tumors. It will break through the situation of dependence on import and imitation of tumor drugs for the country, and form a neck sticking technology in the field of cancer treatment in China Surgical breakthrough played a positive role. After pregnancy, do not let the wife do these five kinds of housework, the husband should be responsible for it, otherwise it is easy to hurt the fetus!